Back to Search Start Over

Assessment of potential drug-drug interactions in hospitalized patients with infectious diseases: an experience from a secondary care hospital [version 2; peer review: 2 not approved]

Authors :
Javedh Shareef
Sathvik Belagodu Sridhar
Abu Nawa Ahmad Ismail
Padma G.M. Rao
Rashid Ain Ur
Author Affiliations :
<relatesTo>1</relatesTo>Department of Clinical Pharmacy & Pharmacology, RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah, 11172, United Arab Emirates<br /><relatesTo>2</relatesTo>Internal Medicine Specialist, Ibrahim Bin Hamad Obaidullah Hospital, Ras Al-Khaimah, Ras al Khaimah, 11172, United Arab Emirates
Source :
F1000Research. 13:164
Publication Year :
2024
Publisher :
London, UK: F1000 Research Limited, 2024.

Abstract

Background Polypharmacy is common among hospitalized patients with infectious infections owing to comorbidities or concomitant illnesses. This raises the likelihood of drug-drug interactions and creates uncertainty for healthcare providers. This study aimed to assess the potential drug-drug interactions (pDDIs) among hospitalized patients with infectious diseases in a secondary care hospital. Methods A prospective observational study was conducted in the internal medicine ward for six months after the ethics committee’s approval. Data were collected from patient case records, and prescriptions were screened for pDDIs from a portable electronic physician information database (PEPID) resource analyzed using SPSS, version 27.0. Results In total, 148 patient case records were analyzed, and 549 pDDIs were identified, with 66.8% having at least one or more DDIs. The mean number of drug interactions was 3.70 ± 4.58 per prescription. The most frequently encountered drug interactions were drug combinations such as bisoprolol with atorvastatin and aspirin with tazobactam/piperacillin. Bivariate analysis showed that age, comorbidities, length of hospital stay, and the number of drugs prescribed were risk factors associated with DDIs (p Conclusions This study observed the prevalence of DDIs in hospitalized patients with infectious diseases of ‘moderate’ severity. Prescription screening using a drug information database assists in early identification and prevention of DDIs, enhancing drug safety and quality of patient-centered care.

Details

ISSN :
20461402
Volume :
13
Database :
F1000Research
Journal :
F1000Research
Notes :
Revised Amendments from Version 1 Title: No changes were made in the title ‘Assessment of potential drug-drug interactions in hospitalized patients with infectious diseases: an experience from a secondary care hospital’. Abstract: Under the ‘introduction’ section editing and language review was done and the sentence was corrected as ‘Polypharmacy is widespread among hospitalized patients with infectious disease infections due to comorbidities or other concomitant illnesses’. Also in the ‘conclusion’ section ‘Prescription screening using a drug information database assists in identifying and preventing DDIs early, enhancing drug safety and quality of patient-centered care’. No changes were done in Authors list, figures, tables and data that was provided in the version 1 However, Editing and language review was done through the text under each section of the manuscript. Introduction: Description of infection diseases is provide by incorporating the following sentence. Infectious diseases are conditions caused by microscopic organisms such as bacteria, viruses, fungi, or parasites that spread from one person to another. Methods: The following changes were done under this section in the manuscript. • A statement of confirmation that the study conforms to recognized ethical standards should be included. ‘This study was performed per the principles outlined in the Declaration of Helsinki, the US Federal Policy for the Protection of Human Subjects (Common Rule), and the European Medicines Agency Guidelines for Good Clinical Practice’. • ‘Method’ section of the manuscript has been described in detail to include details about the study setting, ethical approval, inclusion/exclusion criteria, study duration, reference to the drug interaction tools used, and method of assessing drug-drug interactions., , [version 2; peer review: 2 not approved]
Publication Type :
Academic Journal
Accession number :
edsfor.10.12688.f1000research.143186.2
Document Type :
research-article
Full Text :
https://doi.org/10.12688/f1000research.143186.2